449 related articles for article (PubMed ID: 26378179)
1. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
[TBL] [Abstract][Full Text] [Related]
2. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
6. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
7. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
8. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Group O Resistance Against Integrase Inhibitors.
Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
[TBL] [Abstract][Full Text] [Related]
10. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
11. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.
Wares M; Hassounah S; Mesplède T; Sandstrom PA; Wainberg MA
Antimicrob Agents Chemother; 2015 Apr; 59(4):1942-9. PubMed ID: 25583721
[TBL] [Abstract][Full Text] [Related]
12. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
[TBL] [Abstract][Full Text] [Related]
13. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
14. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
[TBL] [Abstract][Full Text] [Related]
15. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.
Van Rompay KKA; Hassounah S; Keele BF; Lifson JD; Ardeshir A; Watanabe J; Pham HT; Chertova E; Sowder R; Balzarini J; Mesplède T; Wainberg MA
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381490
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
19. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
Weber J; Rose JD; Vazquez AC; Winner D; Margot N; McColl DJ; Miller MD; Quiñones-Mateu ME
PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.
Anstett K; Mesplede T; Oliveira M; Cutillas V; Wainberg MA
J Virol; 2015 Apr; 89(8):4681-4. PubMed ID: 25653436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
